Evidence map›Paper›PMID 42300735›Full record

ArticleJournal of virology2026

A VSV-vector vaccine simultaneously targeting H5N1 hemagglutinin and matrix protein 2 induces robust neutralizing and ADCC antibody responses and provides full protection against lethal H5N1 infection in a mouse model.

Zhujun Ao, Robert Vendramelli, Maryann Buyu, Thang Truong, Dayu Liu, Nick Gao, Heqing Ma, Stephen Amos, Peter Lawrynuik, Maurice Nyamekye and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Zhujun AoLaboratory of Molecular Human Retrovirology, University of Manitoba, Winnipeg, Manitoba, Canada.
Robert VendramelliSpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Maryann BuyuLaboratory of Molecular Human Retrovirology, University of Manitoba, Winnipeg, Manitoba, Canada.
Thang TruongSpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Dayu LiuLaboratory of Molecular Human Retrovirology, University of Manitoba, Winnipeg, Manitoba, Canada.
Nick GaoLaboratory of Molecular Human Retrovirology, University of Manitoba, Winnipeg, Manitoba, Canada.
Heqing MaDepartment of Immunology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Stephen AmosLaboratory of Molecular Human Retrovirology, University of Manitoba, Winnipeg, Manitoba, Canada.
Peter LawrynuikLaboratory of Molecular Human Retrovirology, University of Manitoba, Winnipeg, Manitoba, Canada.
Maurice NyamekyeLaboratory of Molecular Human Retrovirology, University of Manitoba, Winnipeg, Manitoba, Canada.
Keith R FowkeDepartment of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.
Peter PelkaDepartment of Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID 0000-0003-0099-0422
Maya ShmulevitzDepartment of Medical Microbiology and Immunology, Li Ka Shing Institute for Virology, University of Alberta, Edmonton, Alberta, Canada.ORCID 0000-0002-8627-068X
Sam K P KungDepartment of Immunology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Darwyn KobasaDepartment of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID 0000-0002-6371-7493
Xiaojian YaoLaboratory of Molecular Human Retrovirology, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID 0000-0002-5022-1309

Funding

CIHR OS1-190775Social Sciences and Humanities Research Council of Canada CBRF2-2023-00217
6 · The paper itself

Abstract

Avian influenza A viruses, especially highly pathogenic avian influenza (HPAI) viruses, pose a significant public health threat, and a multivalent vaccine is the primary prophylactic measure to control these viruses. To establish such a vaccine, we generated two multivalent vesicular stomatitis virus (VSV)-based vaccine candidates that simultaneously target H5N1 hemagglutinin (H5 IMPORTANCE: Avian influenza, especially highly pathogenic avian influenza (HPAI) viruses, can cause a highly contagious airborne disease that poses a significant public health threat. The development of a multivalent vaccine is very important to control these viral infections. In this study, we have developed a multivalent vaccine that simultaneously targets two critical HPAI H5N1 surface viral proteins and fully protects against highly pathogenic H5N1 infection in a mouse model. This study provides convincing evidence for the effectiveness of a multivalent vaccine against highly pathogenic influenza A viruses.

Indexed as

Antibodies, NeutralizingAntibody-Dependent Cell CytotoxicityHemagglutinin Glycoproteins, Influenza VirusInfluenza A Virus, H5N1 SubtypeInfluenza VaccinesOrthomyxoviridae InfectionsViral Matrix ProteinsAnimalsAntibodies, ViralDisease Models, AnimalFemaleGenetic VectorsHumansInfluenza, HumanMiceMice, Inbred BALB CAntibodies, NeutralizingAntibodies, Viralhemagglutinin, avian influenza A virusHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesM2 protein, Influenza A virusProtein Subunit VaccinesViral Matrix ProteinsViroporin ProteinsADCC activityavian influenzaH5N1hemagglutininintranasal vaccinationM2 ectodomainmultivalent influenza vaccineneutralizing antibodyVSV vector

Identifiers

PMID42300735
PMCPMC13386899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.